| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Vemurafenib | FAERS: 9 | US FAERS | |
| 2 | Linezolid | FAERS: 4 | US FAERS | |
| 3 | Ceftriaxone | FAERS: 3 | US FAERS | |
| 4 | Finasteride | FAERS: 2 | US FAERS | |
| 5 | Sorafenib | FAERS: 2 | US FAERS | |
| 6 | liposomal doxorubicin | FAERS: 2 | US FAERS | |
| 7 | liposomal doxorubicin | FAERS: 2 | US FAERS | |
| 8 | ponatinib | FAERS: 2 | US FAERS | |
| 9 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | FAERS: 1 | US FAERS | |
| 10 | Acitretin | FAERS: 1 | US FAERS | |
| 11 | Erlotinib Hydrochloride | FAERS: 1 | US FAERS | |
| 12 | Lenalidomide | FAERS: 1 | US FAERS | |
| 13 | Levetiracetam | FAERS: 1 | US FAERS | |
| 14 | Mexiletine | FAERS: 1 | US FAERS | |
| 15 | Rabeprazole | FAERS: 1 | US FAERS | |
| 16 | Ramipril | FAERS: 1 | US FAERS | |
| 17 | Rivaroxaban | FAERS: 1 | US FAERS | |
| 18 | apixaban | FAERS: 1 | US FAERS | |
| 19 | isoniazid, pyrazinamide, rifampin drug combination | FAERS: 1 | US FAERS | |
| 20 | trametinib | FAERS: 1 | US FAERS | |
| 21 | Ampicillin | Canada Vigilance: 2 | Canada Vigilance | |
| 22 | Betamethasone | SIDER | ||
| 23 | Budesonide | Canada Vigilance: 1 | Canada Vigilance | |
| 24 | Clofibrate | Canada Vigilance: 1 | Canada Vigilance | |
| 25 | Dasatinib | SIDER | ||
| 26 | Dexamethasone | SIDER | ||
| 27 | Etidronic Acid | SIDER | ||
| 28 | Febuxostat | SIDER | ||
| 29 | Lithium Carbonate | Canada Vigilance: 1 | Canada Vigilance | |
| 30 | Ofloxacin | SIDER | ||
| 31 | Sertraline | SIDER | ||
| 32 | Sunitinib | SIDER | ||
| 33 | Zalcitabine | SIDER | ||
| 34 | Zidovudine | SIDER | ||
| 35 | liposomal amphotericin B | SIDER | ||
| 36 | posaconazole | SIDER |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120266
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.